# ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"

> **NIH NIH N01** · BOLDER BIOTECHNOLOGY, INC. · 2023 · $1,650,819

## Abstract

BBT-059, a long-acting IL-11 analog, mitigates hematopoietic acute radiation syndrome (HARS) when administered as late as 48h following acute radiation exposure, a time when most other H-ARS medical countermeasures (MCMs) are not effective. The offeror proposes to complete IND-enabling safety toxicology studies of BBT-059, manufacture a GMP lot of BBT-059, and write and submit an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) to begin testing BBT-059 in humans.

## Key facts

- **NIH application ID:** 10932514
- **Project number:** 75N93023C00011-0-9999-1
- **Recipient organization:** BOLDER BIOTECHNOLOGY, INC.
- **Principal Investigator:** GEORGE COX
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $1,650,819
- **Award type:** —
- **Project period:** 2023-07-01 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10932514

## Citation

> US National Institutes of Health, RePORTER application 10932514, ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE" (75N93023C00011-0-9999-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10932514. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*